Duke University

Baylor College of Medicine

Other

University of Illinois

Ligand Pharmaceuticals, Inc.

Donald P McDonnell

Erik R Nelson

Kaitlyn Andreano

Ching-yi Chang

Stephanie L Gaillard

Suzanne E Wardell

Bert W O'Malley

Elisabetta Vegeto

Ming-Jer Tsai

John D Norris

William T Schrader

John A Katzenellenbogen

Anthony R Means

Teresa A Martin

Julie A Pollock

Nelson Chao

Luigi Racioppi

Wei Huang

Daju Fan

Ashini Wijayaratne

Caroline Connor

Kathryn E Carlson

Jillian Gunther

Alexander Parent

Daniel Frigo

The disclosure provides methods for treating estrogen receptor positive (ER) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ERcancers.

Lasofoxifene treatment of breast cancer

Disclosed herein are methods of treating subjects suffering from estrogen receptor positive cancer of the brain by administering a selective estrogen receptor degrader (SERM). Also disclosed are methods of treating a cancer that is resistant to an estrogen receptor modulator by administering a SERM.

Method of treating cancer using selective estrogen receptor modulators

Provided herein are compositions including a CaMKK2 inhibitor and an anti-cancer therapeutic agent and methods of treating cancer in a subject by administering a therapeutically effective amount of the composition to a subject. The subject may be selected for treatment based on an immune cell measurement of a sample from the subject. Methods of treating cancer by administering a therapeutically effective amount of a CaMKK2 inhibitor, and administering a therapeutically effective amount of an anti-cancer therapeutic agent to the subject are also provided. Kits including combination of a CaMKK2 inhibitor and another anti-cancer therapeutic agent are also provided.

CaMKK2 inhibitor compositions and methods of using the same

Provided herein are compounds, compositions, including pharmaceutical compositions, having anti-cancer activity. Also provided are methods for diagnosing, detecting, and treating cancer in a subject, as well as a method for evaluating cancer stage in a subject, wherein the methods include determining the amount of a Ca/calmodulin dependent kinase kinase (CaMKK) in a sample. Further provided are methods of screening and identifying a compound that inhibits CaMKK.

CaMKK-&#x3b2; as a target for treating cancer

The present disclosure provides tetra-substituted cyclobutane inhibitors of Androgen Receptor Action, and methods of using such inhibitors, for the treatment of hormone-refractory cancers.

Tetra-aryl cyclobutane inhibitors of androgen receptor action for the treatment of hormone refractory cancer

Growing community of inventors

Chapel Hill, NC, United States of America

Donald P McDonnell